Statements Archives

S&P Report Finds Rx Prices Driving Increased Health Care Costs

May 10, 2016

"Annual prescription price hikes are driving the overall increase in health care costs and making health care less affordable for Americans. Today's S&P report confirms what we've been saying — these increases in drug cost are unsustainable — and solutions to promote transparency, increase competition, and focus on value must be advanced," said John Rother, executive director of the Campaign for Sustainable Rx Pricing (CSRxP). Read More

John Rother Statement on IMS Health Report

Apr 14, 2016

“Excessive price hikes on prescription drugs drive up spending year after year with no end in sight. Drug makers' annual habit of demanding a blank check, without reference to any change in value from patients and taxpayers, makes it harder for American families to make ends meet. Ultimately, these price increases make health care more expensive for all of us, even those who don’t use prescription drugs. It’s outrageous.” Read More

John Rother Statement on Reuters Analysis of Prescription Drug Price Increases

Apr 4, 2016

“This is further evidence that skyrocketing drug prices are more widespread than a few bad actors. When major drug companies hike prices on common prescription drugs, Americans suffer. Families are forced to decide between paying for prescriptions or paying bills, and that’s wrong.” Read More

Senate Special Committee on Aging Examines Drug Pricing

Mar 17, 2016

"Companies are buying decades-old prescription drugs and jacking up prices on vulnerable patients. It’s unconscionable. We need more transparency and competition in the prescription drug market to protect Americans from this appalling practice.” Read More

FDA to Prioritize Generic Drug Applications

Mar 15, 2016

"Recently, the FDA took an important first step in acknowledging the need to introduce more competition by prioritizing generic applications where there is no competition. This effort will give patients better access to affordable treatments," said John Rother, executive director of the Campaign for Sustainable Rx Pricing. Read More

AARP Report Finds Dramatic Prescription Price Hikes

Feb 29, 2016

“Today’s AARP report provides new evidence that drug companies are raising prescription drug prices on patients indiscriminately. Specialty and branded drugs alike are going up six times faster than inflation. The exorbitant increases make health care more expensive for families, taxpayers, and job creators and put a major strain on federal and state governments. It's going to take market-based policy solutions to deal with this unsustainable trend.” Read More

John Rother Statement on House Oversight Committee Hearing

Feb 4, 2016

“Prescription drug cost hikes are not limited to companies run by people like Martin Shkreli; they are commonplace in the pharmaceutical industry. This issue transcends political party lines because consumers, patients, and public programs across the country simply cannot afford higher prices for medication." Read More

Pfizer Hikes Prices on More Than 100 Existing Prescription Drugs

Jan 11, 2016

“Again and again, drug companies like Pfizer raise prices of prescriptions that have already been on the market for years which hurts patients trying to make ends meet and public programs dealing with difficult budgets. These increases, compounded year after year, are simply unsustainable. It’s not about innovation or research; it’s price gouging.” Read More

CMS Introduces Medicare Drug Spending Dashboard

Dec 22, 2015

This afternoon, the Centers for Medicare & Medicaid Services took an important step in the drug pricing conversation by introducing a tool that will increase transparency. To develop realistic market-based solutions to unsustainable drug prices requires that everyone focus on value and transparency in drug pricing, and this latest effort from CMS is a positive step.” Read More

Senate Committee Examines Drug Pricing Strategies

Dec 9, 2015

“For a breakthrough medication to be effective, it needs to be affordable, yet drug makers fail time and time again to abide by this fundamental principle. The Campaign commends the Senate Special Committee on Aging for challenging the pharmaceutical industry on the irresponsible pricing strategies that deliberately deny patients and consumers access to affordable treatments." Read More

Part D Enrollees Who Take Specialty Drugs Will See Out-of-Pocket Costs Rise in 2016

Dec 3, 2015

“This latest analysis from the Kaiser Family Foundation paints a troubling picture for the future of the Medicare Part D program and beneficiaries who rely on access to affordable treatments." Read More

Senators Release Report on Hepatitis C Drug Pricing

Dec 1, 2015

“As we all focus on how to ensure patients get the medications they need at an affordable price, we commend Senators Wyden and Grassley for undertaking this important investigation and for raising awareness around this rapidly growing issue for both sides of the aisle." Read More